The role of polymorphic HLA-DR beta chain residues in presentation of viral antigens to T cells by unknown
The Role of Polymorphic HLADRS Chain Residues
in Presentation of Viral Antigens to T Cells
By Robert W. Karr,* Wei-yuan Yu,* Rebecca Watts,'
Karin S. Evans,$ and Esteban Celis#
From the 'Department of Veterans Affairs Medical Center and the Department ofInternal
Medicine, University of Iowa College ofMedicine, Iowa City, Iowa 52242, and
#T Cell Sciences, Cambridge, Massachusetts 02139
Summary
The relative importance of 11 polymorphic positions in the HLADR701 chain in T cell recognition
of foreign antigens was investigated using transfectants expressing mutant DR701 chains as APC
for five rabies virus-specific T cell clones. The results indicate that multiple amino acids, located
in both the fl-strands and ct-helix of DR701 in the model of a class II molecule, are involved
in DR7-restricted T cell recognition of these antigens. Many of the substitutions appeared to
reduce the affinity of an antigenic peptide for the mutant DR7 molecules but did not prevent
binding. The heterogeneity of responses of the three G-specific T cell clones to presentation
of the G11.3 peptide by several of the mutant DR7 molecules indicates that the T cell receptor
(TCR) of each these clones requires a different view of the G11.3/DR7 complex and raises the
possibility that the G11.3 peptide may bind to the DR7 molecule in more than one conformation.
c
lass 11-restricted T cell recognition offoreign antigens,
a central event in the normal function of the immune
system, requires the formation ofa trimolecular complex con-
sisting ofa class II molecule, a foreign antigenic peptide, and
a TCR. This is a highly specific interaction in which the TCR
recognizes a unique three-dimensional conformation of the
class II-peptide complex. The demonstration ofdirect binding
of antigenic peptides to class II molecules has greatly facili-
tated the current understanding of these interactions (1, 2).
Amino acid differences or polymorphisms among class II mol-
ecules play a very important role in the specificity of these
interactions and are the basis for class 11-restricted T cell
recognition. Although class II polymorphisms in general
appear to be important in peptide binding and TCR in-
teractions, the contributions ofindividual amino acids at poly-
morphic positions in these molecules are only beginning to
be understood. In the murine system, several studies using
mutant class II molecules generated by site-directed muta-
genesis have provided insight into the contributions of in-
dividual amino acids in these molecules to restricted recogni-
tion of foreign antigens by T cells (3-8). However, similar
analyses of human class II molecules have not been reported.
Elucidation of the ways in which HLA classII polymorphisms
influence these complex interactions will have important im-
plications for understanding the basis for the association of
certain class 11 alleles with specific diseases and for the devel-
opment of synthetic peptide vaccines.
The recent description of a hypothetical model of MHC
class II molecules (9), extrapolated from the crystal structure
of a class I molecule (10, 11), has been very important in
shaping the current understanding of the contribution ofthe
class II molecule to T cell recognition. The model predicts
that the antigen binding site or groove is formed by the mem-
brane distal al and 01 domains ofclass II molecules that fold
to form a platform of 0-strands which is topped by two cx-
helices, one formed by a portion of the cx chain and the other
by a portion o£ thea chain. Importantly, most of the amino
acids that are polymorphic among class II molecules are lo-
cated in the model at positions in the 0-strands and ct-helices
that are predicted to be important in determining peptide
binding or TCR interactions.
In the studies reported here, we have investigated the role
of human MHC class 11 0 chain allelic polymorphisms in
presentation of viral antigens to T cells using HLADR7-
restricted recognition of rabies virus antigens by human T
cell clones as a model system. Our strategy was to assess the
relative importance of polymorphic positions in the HLA-
DR701 chain in T cell recognition of rabies virus antigens
by using site-directed mutagenesis to produce 11 mutant
DR701 chains with single amino acid substitutions at posi-
tions that are predicted in the class II model to be involved
in peptide binding or TCR interactions. Transfectants ex-
pressing these mutant DR701 chains with the nonpolymor-
phic DRcx chain were used as APC for rabies virus-specific,
DR7-restricted T cell clones. The data indicate that multiple
residues in the 0-strands and a-helix of the DR701 chain
are involved in DR7-restricted recognition offoreign antigens.
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273-283Materials and Methods
cDNA Clones.
￿
Full-length HLA-DR a and /3 chain cDNA
clones in the OkayamaandBerg expression vector pcD(12) or pcD-
SR«296 (13) were used in these studies. The DRB1"07 cDNA,
whichencodes theDR701chain andthe DRAcDNA, which en-
codestheDRachain, were isolated from a DR7 library (14). The
DRB1*0401 cDNA (provided by Peter Gregersen, Northshore
University Hospital, Manhasset, NY), which encodes theDw4o1
chain, was cloned from a DR4, Dw4 library (15).
Mutagenesis. The mutagenesis strategy was to produce
DRB1*07 cDNAs in which specific codons had been altered by
mutagenesis to introduceacodonthat encodes theaminoacid found
at thecorresponding position of theDw4o1 chain. Eleven 17-19-
mer mutagenic oligonucleotides were designed to generate these
DR7~1 - Dw4o1 substitutions at positions 11, 13, 30, 37, 57,
60, 67, 70, 71, 74, and 78 of DR701. The oligonucleotides were
synthesized by theDNACore of theUniversity of Iowa Diabetes
and Endocrinology Research Center. Site-specific mutagenesis at
positions 9and 67 wasperformedon thedouble-strandedDRB1*07
cDNA using the gapped heteroduplex method of Barbosa et al.
(16), as describedby us elsewhere (17) . The other mutations were
performedusing an in vitromutagenesis system (AmershamCorp.,
Arlington Heights, IL), which is based on the method of Taylor
et al. (18), as describedby us elsewhere(17). Afterthe mutagenesis
and screening, mutant M13 double-stranded DNA was prepared,
andaliquots were digested with BamHI or Sacl and Bsu36I. The
1,300-bp BamHIfragments andthe304-bp SacI-Bsu36I fragments
were recovered from agarose gels andligated into BamHI-digested
pcD vector (mutants at positions 11, 13, and 30) or pcD-SRa296
vector (mutants at positions71 and74), or the Sacl-Bsu36I-digested
pcD vector containing theremainder of theDRBl'07cDNA (mu-
tants at positions37, 57, 60, 67, 70, and 78), respectively. When
theBamHIcDNA fragment wascloned into theexpression vector,
nucleotide sequencing of DNA corresponding to the entire ma-
ture protein wasperformedto confirm that thesequence wasiden-
tical to the DR701 wild-type sequence except for the nucleotide
changesinduced by themutations. When the mutant SacI-Bsu36I
fragment wasreturned to the expression vector, only this portion
of the cDNA was sequenced.
Transfection.
￿
Cells of the DAP.3 subclone of class II-negative
murine L cell fibroblasts were transfected using thecalcium phos-
phateco-precipitation method as described (19). For each transfec-
tion, 20 /Ag of plasmids containing the DR ca chain or (3 chain
cDNA and 1 wg of the pSV2-neo plasmid were used. Class II ex-
pression by G418-resistant Lcells was analyzed usinganti-class II
mAb, indirect immunofluorescence, andflow cytometry, andtrans-
fectants with comparable levels of classII expression were isolated
by simultaneous flow cytometric sorting and cloning as described
(19). The transfectant expressing wild-type DRa:DR701 mole-
cules has been described (19). Cloned transfectants were used in
all studies.
Cell Proliferation Assays.
￿
Therabies virus-specific T cell clones
used in this study were isolated from a CD4*, CD8- T cell line
derived from a healthy male rabies vaccine recipient as described
(20). Clones 1C6 (previously referred to as C6), 1C10 (C10), 1C9
(C9), and 1B8 (B8) have been described (20, 21). 2 x 10° cloned
T cells were incubated with various concentrations of antigen or
peptides in the presence of 1 x 10^ transfected L cells for 3 d in
each well of a96-wellmicrotiter plate (Costar, Cambridge, MA).
The cultures were pulsed during the last 16-20 h with 1 pCi of
[3H]thymidine (NEN-DuPont, Boston, MA) and harvested onto
glass fiber filters. Radioactivity was measured by liquid scintilla-
tion spectroscopy andtheresultsofthecell proliferation assays were
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expressed as counts perminute. Results were calculated from the
mean cpmobtained from duplicate or triplicate determinations and
the SD of the mean was always <10% of the mean.
Antigens.
￿
Synthetic peptides correspondingto portions of the ra-
bies virus glycoprotein (G)t and nucleoprotein (N) were prepared
in Applied Biosystems or Biosearch automated synthesizers. The
amino acid sequences ofthe syntheticpeptides were deducedfrom
the nucleotide sequencesofGandN genesofthe ERA andDUV6
strains. Aminoacid analysis revealed that all peptides were at least
95% pure. Peptides were resuspended in PBS at 1 mg/ml before
their use in tissue culture. Rabies ribonucleoprotein (RNP) com-
plex (provided by Dr. Bernard Dietzschold, Wistar Institute,
Philadelphia,. PA) was purified from lysates of cells infected with
the Pitman Moore strain of rabies virus as described (22). Purified
RNPcomplexes wasshownto be composed mainly of N plus small
amounts (N10%) of the phosphoprotein NS.
Results
11 mutant DR701 chains with single amino acid substi-
tutions were produced by site-directed mutagenesis. In each
mutant, the residue found in the wild-type DR701 chain
was replaced by the residue found at the same position of
another DR01 allele, Dw401(Fig. 1a). As shown schemat-
ically in Fig. 1 b, the residues at positions 11, 13, 30, and
37 are predicted, in the model of a class II molecule (9), to
be locatedin the /3-strands in the floor of the peptidebinding
groove with their side chains pointing up into the binding
groove. The residues at positions 57, 60, 67, 71, 74, and 78
arepredictedto be locatedon the(x-helix with their side chains
pointing in toward thebinding groove, whereas theside chain
ofamino acid 70 is predictedto be pointing up andin toward
the top of the binding groove. The 11 G -+ V, 60 S -+- Y,
67 I -" L, and 71 R - K substitutions are conservative, and
the other substitutions are nonconservative.
L cell transfectants expressing the DRa chain with the
wild-typeDR701 chain or oneof themutant DR701 chains
were produced andcloned transfectants expressing comparable
levels ofDR molecules were selected from each bulk culture
by simultaneous flow cytometric sorting andcloning. 12 trans-
fectants expressing the wild-type or mutant DR7 molecules
were used as APC for 5 DR7-restricted, rabies virus-specific
T cell clones. T cell clones 2C5, 1C6, and 1C10 are spe-
cific for G and recognize G11.3, a 15 amino acid peptide
(DALESIMTTKSVSFR) that corresponds to positions 285-
299 of G. PBMC, but not L cell transfectants, are able to
process and present G to clones 2C5, 1C6, and 1C10 when
purified Gor wholevirusis used as the antigen source. Both
PBMC and DR7-expressing transfectants areable to present
the G11.3 peptide to these clones. Clones 1C9 and 1B8 are
specific for N. L cell transfectants, as well as PBMC, are able
to process and present the relevant N peptides when RNP
is used as the antigen source. In addition to a naturally
processed peptide of N, clone 1B8 also recognizes peptide
13D of N when presentedby PBMC or transfectants. T cell
1Abbreviations used in this paper: G, glycoprotein; N, nucleoprotein;
RNP, ribonucleoprotein.Figure 1 .
￿
(a) The amino acid substitutions (single-letter code) in
mutant DR701 chains produced by site-directed mutagenesis. In
each mutant, the residue found in the DR701 wild-type chain was
replaced by the residue found at the same position of the Dw4/31
chain. (b) The locations of the substituted amino acids in the class 11
model of Brown et al. as described in reference 9. (Reprinted by
permission from Nature 332:845, 1988, Macmillan Magazines
Limited.)
proliferation data from representative experiments are presented
in Tables 1 and 2, and the proliferation induced by each mu-
tant DR7 molecule is presented as a percentage ofthe prolifer-
ation of the same T cell clone in response to the wild-type
DR701 molecule and the same antigen in a reduced form
in Table 3.
When the results with the three G-specific clones (2C5,
1C6, and 1C10) that recognize the G11.3 peptide are consid-
ered, several observations are noteworthy (Tables 1 and 3).
First, at the lowest peptide concentration (0.01 NAg/ml), 10
of the 11 substitutions in DR7#1 caused either complete elimi-
nation or significant reduction in the ability ofthe DR7 mol-
ecule to present the G11.3 peptide to each ofthe T cell clones.
Only the 71 R --> K mutant induced proliferation by clones
2C5 and 1C6 at levels comparable to that induced by the
wild-type molecule. However, at a peptide concentration of
1 1g/ml, nine of the mutants presented peptide G11.3 to at
least one of the clones as efficiently as the wild-type mole-
cule. The 37 F - Y and 60 S -" Y mutants were less efficient
at presentation of G11.3 at 1 Itg/ml to each of the clones.
Only the position 13 and 57 mutants presented the G11.3
peptide (1.0 ug/ml) to all three clones at levels comparable
to the wild-type. Some of the substitutions had very selec-
tive negative effects on presentation of G11.3 to one clone.
For example, the 30 L -+ Y mutant presented peptide (1.0
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jig/ml) very well to clones 1C10 and IC6, but this substitu-
tion completely abrogated recognition by clone 2C5. Like-
wise, the position 67 mutant, with a highly conservative
I - L substitution, presented peptide (1.0 hg/ml) very well
to clone 1C6, moderately well to clone 1C10, and not at all
to clone 2C5. The failure of the position 30 or 67 mutant
to present peptide to clone 2C5 cannot be due to failure of
these mutant DR7 molecules to bind the G11.3 peptide be-
cause these mutants were quite efficient at presentation of
this peptide to the other clones. Therefore, the failure of a
mutant DR7 molecule to present peptide G11.3 to these clones
does not equate with the inability of the mutant molecule
to bind the peptide. Analogous selective effects on the ability
to present G11.3 were found with the position 11, 70, and
78 mutants. Therefore, these data indicate that multiple
DR701 amino acids located in both the 0-strands and ci-
helix in the class II model are involved in the presentation
of the G11.3 peptide to these three clones.
In contrast to presentation of the G11.3 peptide, in which
the peptide probably binds to class II molecules on the sur-
face of the APC, presentation of N to clones 1C9 and 1138
almost certainly involves internalization of RNP, the source
of N in these studies, and subsequent antigen processing and
binding of one or more naturally processed antigenic pep-
tides to DR7 molecules. Although each of the N-specific T
cell clones presumablyrecognizes a different naturally processed
N peptide, the exact sequences ofthese peptides are unknown.
Substitutions at positions 70, 71, 74, and 78 of DR7)31 elim-
inated the ability of the DR7 molecule to present antigen
to the N-specific clones 1C9 and 1138 (Tables 2 and 3). The
substitutions at positions 11, 13, 30, 37, and 60 reduced or
eliminated the ability of these mutants to present N to clone
1C9, regardless of the antigen concentration, whereas the
position 11, 30, and 37 mutants presented N to clone 1138
quite efficiently. These data suggest that these clones recog-
nize different N peptides. The position 57 mutant presented
N to both clones comparablyto the wild-type molecule. Clone
1138 also recognizes 13D, a 15 amino acid peptide that corre-
sponds to positions 121-135 of N (ALTGGMELTRDPTVP).
Eight of the DR7 mutants were unable to present the 13D
peptide to clone 1138 at any antigen concentration. The posi-
tion 11 and 30 mutants induced proliferation by 1138 that
was 23 and 74%, respectively, of that induced by the wild-
type at the highest peptide concentration. In contrast, the
position 57 mutant induced proliferation by 1138 that was
threefold greater than that induced by the wild-type and that
was similar to that obtained with RNP. Thus, the 57 V -
D substitution appears to permit binding of 13D to the DR7
molecule in a conformation that is similar enough to that
of the naturally processed peptide of N to permit recogni-
tion by clone 1138. These data suggest that the naturally
processed N peptide recognized by clone 1138 and peptide
13D are not identical.
As shown in Table 3, the position 11, 13, 30, 57, 67, and
71 mutants induced proliferation by one or more of the T
cell clones that was >120% of the proliferation induced by
the wild-type at the highest antigen concentrations. In addi-
a 11 13 30 37 57 60 67 70 71 74 78
DR701 G
4
Y
4
L
4
F
4
V
4
S
4
I
4
D
4
R
4
Q
4
V
4
Dw4p1 V H Y Y D Y L Q K A YTable 1.
￿
Responses of G-speck T Cell Clones to Peptide G11J Presented by Transfectants Expressing Mutant DR7,81 Chains
" T cell clone.
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Proliferation by T cell clones
APC
Peptide
concentration
,ug/ml
2C5"
G11.3
1C6
G11 .3
cpm x 10 -3
1C10
G11 .3 APC
2C5
G11.3
cpm
IC6
G11.3
x 10-3
Exp. 1 Exp. 2
DR701 0 0.1 0.1 0.3 DR701 1.0 0.2
Wild-type 0.01 19.4 3 .6 4.3 Wild-type 25.6 36.1
0.1 25 .8 13 .7 6.4 32.0 34.9
1 .0 22.9 17.6 4.8 23.9 38.0
DR701 0 0.1 0.1 0 .2 DR701 0.2 0.2
11 G -" V 0.01 ND 0.1 0.3 71 R-K 19.7 37.1
0.1 8 .0 0.2 1.1 33.3 36.1
1 .0 6 .0 4 .9 4.9 32.1 45.6
DR701 0 0.2 0.2 0.2 DR701 0.2 0.3
13 Y - H 0.01 1 .4 0.2 0.4 74 Q -" A 0.3 0.6
0.1 19.2 5.7 5.3 0.4 15.1
1.0 23.2 15.5 8.7 19.7 38.4
DR701 0 0.1 0.3 0.3 Dw4s1 0.2 0.2
30 L - Y 0.01 0.6 0.3 0.6 0.2 0.3
0.1 0.3 5 .6 5.1 0.3 0.3
1 .0 1.1 17.6 7.8 1 .2 2.4
DR701 0 0.2 0.1 0.6
37F-Y 0.01 9.2 0.5 1 .7
0.1 15.8 4.3 5.0
1.0 11.4 10.6 3.4
DR701 0 0.1 0.3 0.7
57V-D 0.01 3.6 0.3 1 .5
0.1 28.5 6.6 3 .2
1 .0 31.6 16.7 4.3
DR701 0 0.1 0.1 0.6
60S - Y 0.1 0.5 0.0 0.8
0.1 8.3 0.2 1.2
1 .0 14.7 3.2 1 .0
DR701 0 0.1 0.5 0.2
67 1 - L 0.01 0.1 1 .0 0.3
0.1 0.1 8.6 2 .5
1 .0 0.6 25 .0 3.1
DR701 0 0.1 0.1 0.5
70 D - Q 0.01 0.1 0.3 0.9
0.1 0.2 7.6 0.6
1 .0 1 .0 17.5 1 .5
DR701 0 0.2 0.2 0.6
78 V - Y 0.01 0.1 0.3 0.8
0 .1 0.7 6.2 1.4
1 .0 7 .3 15 .8 2.0
Dw4o1 0 0.1 0.3 0 .9
0.01 0.1 0.3 0 .8
0.1 0 .1 0.3 1.4
1 .0 0.7 0.4 1.7Table 2.
￿
Responses ofN-specific T Cell Clones to Rabies Virus Antigens Presented by Transfeciants Expressing
Mutant DR7,81 Chains
" T cell clone.
# Peptide 13D.
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Proliferation by T cell clones
APC
Exp. 1
DR701
Antigen
concentration
RNP
fcg/ml
0
IC9'
RNP
cpm
0.3
1138
RNP
x 10-3
0.2
1138
13D
0.2
Antigen
concentration
13D#
jug
0
APC
Exp. 2
DR701
1C9
RNP
0.3
1138
RNP
cpm x 10-3
0.2
1B8
13D
0.2
Wild-type 0.56 5.2 5.1 0.1 0.1 Wild-type 5.2 7.3 1 .0
1 .7 8.6 16.1 6.1 1 .0 8.6 18.1 10.8
5 .0 17.0 26 .1 6.5 10 17.0 36.6 36.7
DR701 0 0.1 0.2 0.2 0 DR7#1 0.2 0.0 0.0
11 G - V 0.56 2.1 13 .0 0.1 0.1 71 R - K 0.2 0.0 0.1
1 .7 5.4 25 .5 0.2 1 .0 0.2 0.1 0.1
5 .0 11.5 32 .4 1 .5 10 0.2 0.1 0.1
DR7,61 0 0.3 0.2 0.2 0 DR7#1 0.2 0.1 0.1
13 Y - H 0.56 0.3 2.2 0.1 0.1 74 Q - A 0.2 0.1 0.1
1 .7 0.3 10.2 0.1 1.0 0.2 0.1 0.1
5.0 0.9 19.4 0.1 10 0.2 0.3 0.1
DR701 0 0.2 0.2 0.2 0 Dw4ol 0.2 0.1 0.1
30L-Y 0.56 1.7 14.2 0.1 0.1 0.2 0.1 0.1
1 .7 5.5 26.7 0.2 1.0 0.2 0.1 0.1
5.0 10.8 28.1 4.8 10 0.2 0.1 0.1
DR701 0 0.3 0.4 0.3 0
37F-Y 0.56 0.9 11 .3 0.4 0.1
1.7 3 .2 19.7 0.3 1.0
5.0 3.8 22.3 0.3 10
DR7#1 0 0.3 0.2 0.2 0
57V --" D 0.56 4.0 6.5 8.7 0.1
1.7 5 .7 21 .1 25 .4 1.0
5.0 14.6 25.4 20.8 10
DR701 0 0.2 0.3 0.3 0
60S-Y 0.56 0.4 1.8 0.2 0.1
1 .7 3.4 7.7 0.3 1.0
5.0 4.3 13.9 0.1 10
DR701 0 0.2 0.2 0.2 0
67 1 - L 0.56 3.1 2.4 0.2 0.1
1 .7 9.0 7.6 0.2 1 .0
5 .0 14.1 18.4 0.1 10
DR791 0 0.1 0.3 0.3 0
70 D --" Q 0.56 0.2 0.3 0.2 0.1
1 .7 0.2 0.2 0.2 1 .0
5 .0 1 .7 0.4 0.1 10
DR701 0 0.4 0.4 0.4 0
78 V - Y 0.56 0.3 0.2 0.3 0.1
1 .7 0.6 0.4 0.3 1 .0
5 .0 0.4 0.6 0.2 10
Dw4#1 0 0.2 0.4 0.4 0
0.56 0.2 0.4 0.3 0.1
1 .7 0.2 0.4 0.3 1.0
5 .0 0.2 0.3 0.2 10tion, the position 11, 30, 37, and 57 mutants induced in-
creased proliferation of clone 1B8 at lower antigen concen-
trations. The position 30 and 57 mutants each induced
increased proliferation by two clones, whereas the position
11, 13, 37, 67, and 71 mutants each induced increasedprolifer-
ation by one clone. The T cell clones showed heterogeneity
in the frequency of these increased proliferative responses when
antigen was presented by the mutant DR7 molecules. Clone
1B8 showed increased proliferation in the recognition of N
with four of the mutants: positions 11, 30, 37, and 57. It
is notable that the responses of 1B8 with the position 11,
30, and 37 mutants were greater than twofold the prolifera-
tive response elicited by the wild-type molecule at the same
antigen concentration. Three ofthe clones showed increased
proliferation in the recognition of peptide G11.3 with one
or two of the mutants: clone 1C10 with the position 13 and
30 mutants, clone 2C5 with the position 57 and 71 mutants,
and clone 1C6 with the position 67 mutant. Only clone 1C9
did not manifest increased proliferation in response to any
of the mutants.
To further investigate the structural constraints on pep-
tide-class II interactions, the DR701 mutant transfectants
were analyzed for their abilities to present other peptides that
are similar to the G11.3 peptide of G to clones 2C5 and 1C6
(Table 4). Peptide G11 is a 41 amino acid peptide that was
first found to contain the epitope recognized by the G-specific
T cell clones (21). Peptide G11.3 is a 15 amino acid peptide
whose sequence is included in the G11 peptide. The G11 and
G11.3 peptides are based on the sequence ofG from the ERA
The proliferation induced by each mutant DR7 molecule at the highest antigen concentration (G11.3, 1.0 Ag/ml; RNP, 5.0 ug/ml; and
13D, 10 ug/ml) is shown as a percentage of the response to the wild-type DR7 molecule by the same T cell clone in the same experi-
ment: -, <20%; +, 20-49%; + +, 50-79%; + + +, 80-120%; + + + +, >120%.
t T cell clone.
4 Antigen.
278
￿
DR/3 Polymorphic Residues in Antigen Presentation
strain of rabies virus. Three single amino acid substitution
variants of the G11.3 peptide were produced based on the
sequence of G from the Duvenhage 6 (DUV6) strain. G-
specific T cell clones 2C5 and 1C6 were previously shown
to recognize ERA strain virus but not DUV6 strain (20 and
our unpublished data). Peptide G11.5 contains a S - T sub-
stitution at the position that corresponds to amino acid 289
of G, G11,6 has a M - I substitution at position 291, and
G11.7 contains a V -> I substitution at position 296. It is
important to note that the G11.5 and G11.7 peptides were
presented efficiently at 0.01 to 1.0 Fig/ml to clones 2C5 and
1C6 by both DR7+ PBMC (data not shown) and the trans-
fectant expressing the wild-type DR7 molecule, Peptide G11.6
is not recognizedby clone 1C6 at any concentration, whereas
half-maximal proliferation ofclone 2C5 in response to G11.6
presented by the wild-type DR7 molecule (PBMC or trans-
fectant) occurred at 100-fold higher concentration of G11.6
than was required for G11.3, G11,5, or G11.7 (data not shown).
The proliferation data for clones 2C5 and 1C6 in response
to presentation of these peptides by the position 11, 13, and
60 DR701 mutants are shown in Table 4. Only the position
57 mutant presented G11.6 to clone 2C5 (data not shown) .
For the position 30, 37, 57, 67, 70, and 78 DR701 mutants,
the results with the presentation of the G11, G11.5, and G11.7
peptides to clone 2C5 and the G11 .5 and G11.7 peptides to
clone 1C6 were comparable to those found with the presen-
tation of G11.3 to these clones by each of the mutants in
Table 1 (data not shown). However, there was considerable
heterogeneity in the ability of the position 11, 13, and 60
Table 3. Summary of T Cell Responses to Rabies Vine Antigens Presented
Proliferation
by Transfectants
of T cells'
Expressing Mutant DR7,B1 Chains
2C5t 1C6 1C10 1C9 1B8 1B8
APC
DR701 G113§ G11.3 G11.3 RNP RNP 13D
11 G- V + + +++ ++ ++++ +
13 Y -" H +++ +++ ++++ - ++ -
30L- Y - +++ ++++ ++ +++ ++
37F-Y ++ ++ ++ + +++ -
57V- D ++++ +++ +++ +++ +++ ++++
60S-Y ++ - + + ++ -
671-L - ++++ ++ +++ ++ -
70D --" Q - +++ + - - -
71R-K ++++ +++ ND - - -
74Q-A +++ +++ ND - - -
78V-Y + +++ + - - -Table 4.
￿
T Cell Responses to Peptides of Rabies Virus Glycoprotein Presented by Transfectants Expressing Mutant DR7,81 Chains
Peptides
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323
G11 CLDALESIMTTKSVSFRRLSHLRKLVPGFGKAYTIFNKTLM
G11.3 DALESIMTTKSVSFR
G11.5 DALE_TIMTTKSVSFR
G11.6
￿
DALESI_I TTKSVSFR
G11.7
￿
DALESIMTTKSISFR
DR701 mutants to present the different peptides. Although
the G11.3 peptide sequence is contained within the G11 se-
quence, G11 and G11.3 were recognized differently by clone
2C5 in the context of the position 11 and 13 DR701 mu-
tants. It is important to note that the molar dose-response
curves for presentation of G11 and G11.3 by the wild-type
DR7 molecule to clone 2C5 are indistinguishable (data not
shown). Peptide G11 was presented very efficiently by the
11 G -> V mutant, whereas the presentation of G11.3 by
this mutant was considerably diminished compared with the
wild-type. In contrast, the 13 Y -+ H mutant, which presented
the G11.3 peptide (1.0 jig/ml) equivalently to the wild-type,
was unable to present the G11 peptide to clone 2C5 . The
additional COOH-terminal amino acids in G11, compared
with G11.3, may interfere with binding of this peptide to
the position 13 mutant, but on the other hand, may enhance
binding to the position 11 mutant.
Comparison of the abilities of the mutant DR7 molecules
to present the G11.3, G11.5, and G11.7 peptides that differ
only by single amino acid substitutions revealed several in-
teresting findings (Table 4). Clone 1C6, which proliferated
at only 28% of that induced by the wild-type molecule in
response to the G11.3 peptide (1 ttg/ml) presented by the
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Proliferation by T cell clones
Proliferation induced by each transfectant expressing a mutant DR701 chain is expressed as a percentage of the proliferation induced in
the same experiment by the transfectant expressing the DR701 wild-type molecule.
t T cell clone.
5 Peptide.
Discussion
11 G --> V mutant, responded to peptides G11.5 and G11.7
presented by this mutant at 86 and 92% of that induced by
the wild-type molecule, respectively. The 60 S - Y mutant
had a similar pattern with clone 1C6: negligible presenta-
tion of G11.3 and very efficient presentation of G11.5 and
G11.7. The 13 Y -" H mutant presented both the G11.3 and
G11.7 peptides (1 I~g/ml) to clone 2C5 as efficiently as the
wild-type molecule. However, the ability of the position 13
mutant to present peptide G11.5 to done 2C5 was significantly
reduced. In contrast, all three peptides were presented
efficiently by the position 13 mutant to clone 1C6 at peptide
concentrations of 1 I~g/ml.
The data presented here indicate that multiple amino acids,
located in both the a-strands and a-helix of DR701 in the
class II model (9), are involved in DR7-restricted T cell rec-
ognition of rabies virus antigens. When transfectants ex-
pressing the mutant DR7 molecules were used as APC, each
of the five rabies virus-specific T cell clones had a different
reactivitypattern, emphasizing the diversity of the DR7 mol-
ecule/antigenic peptide/TCR trimolecular complexes involved.
APC
Peptide
concentration G11S G11.3
2C5t
G11.5 G11.7 G11.3
1C6
G11.5 G11.7
P's/M1
11 G - V 0.01 118 ND 2 1 2 28 25
0.1 63 31 1 7 2 51 55
1.0 91 26 2 74 28 86 92
13 Y - H 0.01 2 7 2 3 7 71 57
0.1 3 74 1 47 42 82 67
1.0 4 101 33 112 88 98 86
60S-Y 0.01 19 3 2 2 1 15 6
0.1 31 32 3 41 2 58 57
1.0 38 64 46 87 18 91 88The effects of some substitutions were highly selective. For
example, at the highest antigen concentrations, the position
13 mutant induced proliferation by the three G-specific and
one of the N-specific T cell clones that was 75% or greater
of that induced by the wild-type molecule, but was unable
to present N to clone 1C9 at any antigen concentration. The
position 60 substitution had the most negative effect on the
ability of the DR7 molecule to present antigens to the clones.
The conservative 71 R - K substitution had little effect on
the recognition of the G peptide G11.3 by clones 2C5 and
1C6, but it completelyeliminated recognition ofN by clones
1C9 and 1138. Taken together, the results are consistent with
the predictions of the class II model that the amino acids
analyzed are important in peptide binding or TCR interactions.
Three aspects of the experimental system used in these
studies should be emphasized. First, the amino acids sub-
stituted in the DR701 chain were those found at the same
positions in another DR01 chain, Dw401. Second, the trans-
fectants expressing wild-type or mutant DR7 molecules that
were used as APC in these studies expressed comparable levels
of DR7 molecules based on indirect immunofluorescence and
flow cytometry. Finally, the molecules containing the mu-
tant DR701 chains did not seem to have grossly altered con-
formations. 10 of the 11 mutant DR7 molecules induced
proliferation by one or more of the rabies virus-specific T
cell clones that was equivalent to that induced by the wild-
type molecule, and the position 60 mutant induced prolifer-
ation by two of the clones that was >50% of that induced
by the wild-type. Moreover, in an allospecific system, each
of the mutant molecules was able to induce proliferation by
at least one DR7-allospecific clone that was comparable to
that induced by the wild-type molecule (Rosen-Bronson, S.,
W Yu, and R. W. Karr, manuscript submitted for publica-
tion). Therefore, this experimental system permits a reason-
able analysis of the structure-function relationships of DR7
molecules.
In the class II model, the amino acids at positions 11, 13,
30, and 37 in the 0-strands on the floorof thepeptide binding
groove and the amino acids at positions 57, 60, 67, 71, 74,
and 78 along the (x-helix are predicted to be involved in pep-
tide binding (9). However, because of their positions, it is
also possible that some or all of these residues on the a-helix
interact directly with TCR. Substitutions at each of these
positions, except position 57, in the DR701 chain reduced
or eliminated the ability of each mutant molecule to present
antigen to at least one of the T cell clones, indicating that
the amino acids at these positions in the wild-type DR701
chain contribute to antigen-specific T cell recognition. In a
previous study by Mellins et al. (23), a substitution in the
DR3#1 chain at position 9, which is also predicted to be
located on a,3-strand and to be involved in peptide binding,
caused loss ofDR3-restricted antigen presentation. Based on
the class II model, the predicted functional role ofthe amino
acid at position 70 is less clear. The orientation of the side
chain of the amino acid at position 70 is predicted to be
up and in toward the top of the peptide binding site. This
predicted upward orientation is in contrast to most of the
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other putative peptide binding residues on the a-helix, whose
side chains are predicted to point in toward the site. There-
fore, this residue is a strong candidate for direct interaction
with TCR or antibody. However, because of the predicted
orientation of the side chain, it is also possible that, in some
cases, residue 70 is involved in peptide binding. Indeed, the
dose-response with the position 70 mutant in the presenta-
tion of the G11.3 peptide to clone 1C6 suggests that position
70 is involved in peptide binding in this case. If residue 70
were involved solely in direct TCR interaction in the recog-
nition of G11.3 by 1C6, a dose-related increase in the ability
of the molecule to present antigen would not be expected.
The position 70 substitution, however, eliminated or sig-
nificantlyreduced the ability of the DR7 molecule to present
antigen to the other four clones. The position 70 substitu-
tion had a similar negative effect on DR7 allorecognition
by five of six clones analyzed (Rosen-Bronson, S., W Yu,
and R. W Karr, manuscriptsubmitted for publication). There-
fore, Asp at position 70 ofDR701 appears to play a central
role in DR7-restricted T cell recognition.
The results with the DR7)31 57 V - D mutant warrant
comment in the context of predictions of the class II model.
In many murine and human class 11 0 chains, the Asp at po-
sition 57 is predicted to form a salt bridge with Arg at posi-
tion 76 of classII a chains (9). Because the wild-type DR7#1
chain has Val 57, the wild-type DR7 molecule probably does
not have a salt bridge at the right end of the peptide binding
groove. The predicted presence of a salt bridge in the 57
V -" D mutant might be expected to cause a significant change
in the conformation of this mutant DR7 molecule, compared
with the wild-type DR7 molecule. Surprisingly, however,
the position 57 mutant efficiently presented antigen to each
of the G- or N-specific clones at the highest antigen concen-
trations. These results suggest that the 57 V --> D substitu-
tion has not caused a major conformational change in the
molecule and that the reduced stimulation of the G-specific
clones at 0.01 Wg/ml of the G11.3 peptide may reflect subtle
changes in peptide affinity, as noted below. These data may
also be interpreted to indicate that the substituted Asp 57
in the mutant DR701 chain does not participate in the for-
mation of a salt bridge, perhaps because of structural con-
straints imposed by sequences elsewhere in the chain.
One striking finding with presentation of the G11.3 pep-
tide to the three G-specific clones is that, at the highest pep-
tide concentration, many of the mutant DR7 molecules in-
duced proliferation by one or more clones equivalent to that
induced by the wild-type molecule, whereas at the lowest
peptide concentration, these mutant molecules were unable
to induce significant proliferation by the same clones. This
phenomenon was observed with the substitutions at posi-
tions 11, 13, 30, 57, 67, 70, 74, and 78. For example, at a
G11.3 concentration of 1.0 /Ag/ml, the position 13 mutant
induced proliferation by clones 1C10, 2C5, and 1C6 that was
182, 101, and 88% of that induced by the wild-type DR7
molecule, respectively. In contrast, at a peptide concentra-
tion of0.01 jug/ml, this mutant induced proliferation by these
clones that was only 9, 7, and 7% of that induced by thewild-type, respectively. These data suggest that each of the
substitutions at positions 11, 13, 30, 57, 67, 70, 74, and 78
has reduced the affinity of G11.3 for the mutant DR7 mole-
cules. Presumably, on both wild-type and mutant DR7 mol-
ecules, the G11.3 peptide must displace endogenous or exog-
enous peptides that are already bound to the DR7 molecule
when G11.3 is added to the proliferation assay. At a low pep-
tide concentration, G11.3 may not compete effectively for
binding because of the decreased affinity due to the substitu-
tions in DR701, resulting in the inability of these mutant
molecules to present the peptide to any of the T cell clones.
However, at high peptide concentration, the equilibrium may
be shifted in favor of G11.3 binding, in spite of the reduced
affinity. In addition, the substitutions may also affect the affini-
ties of the peptides already bound to DR7 molecules, perhaps
making their displacements more difficult. It is noteworthy
that this marked contrast between inability to present an-
tigen at low peptide concentration and presentation equiva-
lent to the wild-type molecule at high peptide concentration
was noted only with the recognition of the G11.3 peptide
by the three G-specificclones; this phenomenon was not noted
with presentation of N by the mutant molecules.
Considerable heterogeneity of responses of the three G-
specific T cell clones to presentation of the G11.3 peptide by
several of the mutant DR7 molecules was observed. For ex-
ample, at a peptide concentration of 1.0 jig/ml, the position
30 mutant induced proliferation by clones 1C6 and 1C10 that
was equivalent to or greater than that induced by the wild-
type moleculebut was unable to present G11.3 to clone 2C5
at any peptide concentration. Similar heterogeneous responses
of these T cell clones were observed with the position 11,
67, 70, and 78 mutants. This heterogeneity of T cell response
patterns indicates that at least two, and probably three, dis-
tinct T cell recognition determinants are generated by the
G11.3 peptide and the DR7 molecule. Therefore, these three
T cell clones appear to have different fine specificities for the
same peptide/class II complex and to be differentially sensi-
tive to several of the DR701 mutations. These results may
be interpreted to indicate that the G11.3 peptide binds to the
DR7 molecule in multiple conformations. The possibility
that one peptide may bind to a classII molecule in more than
one conformation has previously been suggested based on
studies in the murine system (24, 25) . In this construct, a
given substitution in DR701 might alter or prevent the
binding ofG11.3 in one conformation, whilehaving no effect
on the binding of G11.3 in a second conformation. An alter-
native interpretation is that each TCR requires a different
view of the G11.3/DR7 complex in which the peptide is
bound in one conformation at a single site (26, 27). In this
interpretation, a substitution in DR701 altered the confor-
mation of the G11.3/DR7 complex required by the clone
that does not recognize the complex, whereas the conforma-
tions required by the other clones were maintained. There-
fore, we envision that some antigenic peptides may bind to
a given class II molecule in only one conformation at a single
site, while others may bind in multiple conformations to the
same molecule. It is important to note that the results indi-
cate that the G11.3 peptide was bound to each of the mutant
DR7 molecules; therefore, measurement of G11.3 binding
to mutant DR7 molecules in a direct binding assay would
not distinguish between these two interpretations.
The data with the three G peptides that differ by single
amino acid substitutions offer some insights into the com-
plex interactions that are required for the formation of a
productivecomplex of class II, antigenic peptide, and TCR.
As noted previously, each of these peptides was presented
efficiently to clones 2C5 and 1C6 by the wild-type DR7 mol-
ecule. The position 13 mutant presented the G11.3, G11.5,
and G11.7 peptides to clone 1C6 but presented only the G11.3
and G11.7 peptides to clone 2C5. Therefore, the combina-
tion of Tyr at position 289 of the peptide and the 13 Y -->
H substitution in DR701 prevented recognition by clone 2C5.
The contrast between the efficient presentation of the G11.5
and G11.7 peptides to clone 1C6 by the position 11 and 60
mutants and the markedly reduced ability of these mutants
to present G11.3 to this clone is also informative. The other
seven mutants tested as APC for presentation of these pep-
tides to 1C6 were each able to present all three peptides. In
regard to the peptide, these data indicate that it is recognized
with Ser at position 289 (G11.7) or with Val at position 296
(G11.5), but not when the peptide has both Ser 289 and Val
296 (G11.3). Therefore, the combination of Ser 289 and Val
296 in the peptide and either the 11 G --" V or 60 S -> Y
substitution in DR701 prevents recognition of G11.3 by 1C6.
This could result from the prevention of G11.3 binding by
the substitutions, or if binding does occur, the inability of
1C6 to recognize the resulting DR7/G11.5 complexes.
The results of these studies emphasize the complexity of
the interactions of classII molecules, antigenic peptides, and
TCR and suggest that the diversity of these interactions is
greater than previously appreciated. Because ofthis apparent
complexity and the limitations of the methods of analysis,
the results of studies such as these are often difficult to inter-
pret . However, as the understanding of MHC-restricted,
antigen-specific T cell recognition continues to be refined,
the possibility that the same antigenic peptide is bound to
a specific MHC molecule in more than one conformation
must be considered. This diversity ofthe same peptide/MHC
complex maybe related to the observed heterogeneity of TCRs
that recognize the same complex. Ultimately, determination
of the three-dimensional structures of multiple MHC mole-
cule/peptide/TCR complexes will be required to resolve these
issues. Based on the results presented here, the trimolecular
complexes of DR7/G11.3 peptide and the TCR of clone 2C5
or clone 1C6 would be excellent candidates for these studies.
We thank Vickie Weidner and Sherry Brown for preparation ofthe manuscript; and Charles Lutz, Sandra
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